These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

604 related items for PubMed ID: 32967963

  • 1. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A, Boampong D, Elegunde B, Panwar K, Fleury M, Li S, Zhao Q, Xia N, Christensen ND, Beddows S.
    J Virol; 2020 Nov 23; 94(24):. PubMed ID: 32967963
    [Abstract] [Full Text] [Related]

  • 2. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
    Godi A, Bissett SL, Miller E, Beddows S.
    J Gen Virol; 2017 Jul 23; 98(7):1755-1761. PubMed ID: 28691664
    [Abstract] [Full Text] [Related]

  • 3. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
    Bissett SL, Mattiuzzo G, Draper E, Godi A, Wilkinson DE, Minor P, Page M, Beddows S.
    Vaccine; 2014 Nov 12; 32(48):6548-55. PubMed ID: 25203446
    [Abstract] [Full Text] [Related]

  • 4. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
    Bissett SL, Godi A, Fleury MJ, Touze A, Cocuzza C, Beddows S.
    J Virol; 2015 Aug 12; 89(15):7748-57. PubMed ID: 25995264
    [Abstract] [Full Text] [Related]

  • 5. Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.
    Godi A, Facchetti A, Bissett SL, Cocuzza C, Miller E, Beddows S.
    J Virol; 2015 Dec 30; 90(6):3247-52. PubMed ID: 26719255
    [Abstract] [Full Text] [Related]

  • 6. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
    Ahmed AI, Bissett SL, Beddows S.
    Infect Genet Evol; 2013 Aug 30; 18():151-9. PubMed ID: 23722024
    [Abstract] [Full Text] [Related]

  • 7. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
    Oumeslakht L, Ababou M, Badaoui B, Qmichou Z.
    Gene; 2021 May 25; 782():145533. PubMed ID: 33636291
    [Abstract] [Full Text] [Related]

  • 8. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
    Godi A, Kemp TJ, Pinto LA, Beddows S.
    J Infect Dis; 2019 Nov 06; 220(12):1940-1945. PubMed ID: 31412122
    [Abstract] [Full Text] [Related]

  • 9. Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies.
    Godi A, Bissett SL, Masloh S, Fleury M, Li S, Zhao Q, Xia N, Cocuzza CE, Beddows S.
    J Gen Virol; 2019 Feb 06; 100(2):237-245. PubMed ID: 30657447
    [Abstract] [Full Text] [Related]

  • 10. Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies.
    Godi A, Martinelli M, Haque M, Li S, Zhao Q, Xia N, Cocuzza CE, Beddows S.
    J Infect Dis; 2018 Oct 05; 218(10):1611-1621. PubMed ID: 29905865
    [Abstract] [Full Text] [Related]

  • 11. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.
    Virology; 2007 Feb 20; 358(2):266-72. PubMed ID: 17010405
    [Abstract] [Full Text] [Related]

  • 12. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H, Schmitt M, Böhmer G, Kopp-Schneider A, Müller M.
    Int J Cancer; 2013 Feb 01; 132(3):E139-48. PubMed ID: 22961598
    [Abstract] [Full Text] [Related]

  • 13. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C, Roden RBS, Kirnbauer R.
    Virus Res; 2017 Mar 02; 231():166-175. PubMed ID: 27889616
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X, Zhang T, Liu H, Hao Y, Liao G, Xu X.
    Hum Vaccin Immunother; 2018 Mar 02; 14(8):2025-2033. PubMed ID: 29683766
    [Abstract] [Full Text] [Related]

  • 17. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 18. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E, Peabody J, Peabody DS, Chackerian B.
    PLoS One; 2011 Jul 15; 6(8):e23310. PubMed ID: 21858066
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.